Nanjing Leads Biolabs Co.,Ltd
Quick facts
Phase 3 pipeline
- Tislelizumab Injection · Oncology
Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells.
Phase 1 pipeline
- Axitinib Tablets · Oncology
Axitinib is a selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). - LBL-015 for Injections
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: